Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease

被引:0
作者
Gyorgy Baffy
机构
[1] VA Boston Healthcare System and Brigham and Women’s Hospital,Department of Medicine
[2] Harvard Medical School,undefined
来源
Digestive Diseases and Sciences | 2018年 / 63卷
关键词
Sinusoidal homeostasis; Endothelial dysfunction; Hepatic venous pressure gradient; Intrahepatic vascular resistance;
D O I
暂无
中图分类号
学科分类号
摘要
Nonalcoholic fatty liver disease (NAFLD) advanced to cirrhosis is often complicated by clinically significant portal hypertension, which is primarily caused by increased intrahepatic vascular resistance. Liver fibrosis has been identified as a critical determinant of this process. However, there is evidence that portal venous pressure may begin to rise in the earliest stages of NAFLD when fibrosis is far less advanced or absent. The biological and clinical significance of these early changes in sinusoidal homeostasis remains unclear. Experimental and human observations indicate that sinusoidal space restriction due to hepatocellular lipid accumulation and ballooning may impair sinusoidal flow and generate shear stress, increasingly disrupting sinusoidal microcirculation. Sinusoidal endothelial cells, hepatic stellate cells, and Kupffer cells are key partners of hepatocytes affected by NAFLD in promoting endothelial dysfunction through enhanced contractility, capillarization, adhesion and entrapment of blood cells, extracellular matrix deposition, and neovascularization. These biomechanical and rheological changes are aggravated by a dysfunctional gut–liver axis and splanchnic vasoregulation, culminating in fibrosis and clinically significant portal hypertension. We may speculate that increased portal venous pressure is an essential element of the pathogenesis across the entire spectrum of NAFLD. Improved methods of noninvasive portal venous pressure monitoring will hopefully give new insights into the pathobiology of NAFLD and help efforts to identify patients at increased risk for adverse outcomes. In addition, novel drug candidates targeting reversible components of aberrant sinusoidal circulation may prevent progression in NAFLD.
引用
收藏
页码:563 / 576
页数:13
相关论文
共 426 条
[1]  
Loomba R(2013)The global NAFLD epidemic Nat Rev Gastroenterol Hepatol 10 686-690
[2]  
Sanyal AJ(2016)Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes Hepatology 64 73-84
[3]  
Younossi ZM(2008)Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome Cleve Clin J Med 75 721-728
[4]  
Koenig AB(2016)Natural history of nonalcoholic fatty liver disease Dig Dis Sci 61 1226-1233
[5]  
Abdelatif D(2017)Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis Hepatology 65 1557-1565
[6]  
Fazel Y(2017)Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD J Hepatol 67 1265-1273
[7]  
Henry L(2000)Complications of cirrhosis. I. Portal hypertension J Hepatol 32 141-156
[8]  
Wymer M(2008)Portal hypertension and its complications Gastroenterology 134 1715-1728
[9]  
Kim CH(2010)Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis Eur J Gastroenterol Hepatol 22 1449-1457
[10]  
Younossi ZM(2012)Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease Clin Gastroenterol Hepatol 10 e1022-290